NEW YORK (360Dx) – Copenhagen-based BluSense Diagnostics is developing a test that may solve one of the most challenging issues in the accurate detection and measurement of Zika — false positives triggered by cross reactivity from closely related infectious diseases to Zika, such as dengue and chikungunya.
The company expects to complete the development of a dengue assay this year and launch it on a centrifugal microfluidic immunoassay platform early next year. Later in 2018, it plans to release a combination assay on the same platform that can differentiate dengue from Zika.